Specify a stock or a cryptocurrency in the search bar to get a summary
Reviva Pharmaceuticals Holdings Inc.
RVPHReviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention"deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California. Address: 10080 N. Wolfe Road, Cupertino, CA, United States, 95014
Analytics
WallStreet Target Price
15.2 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures RVPH
Dividend Analytics RVPH
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History RVPH
Stock Valuation RVPH
Financials RVPH
Results | 2019 | Dynamics |